title: Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication.
abstract: Productive infection and replication of herpesviruses usually occurs in growth-arrested cells, but there has been no direct evidence in the case of Epstein-Barr virus (EBV), since an efficient lytic replication system without external stimuli does not exist for the virus. Expression of the EBV lytic-switch transactivator BZLF1 protein in EBV-negative epithelial tumor cell lines, however, is known to arrest the cell cycle in G(0)/G(1) by induction of the tumor suppressor protein p53 and the cyclin-dependent kinase (CDK) inhibitors p21(WAF-1/CIP-1) and p27(KIP-1), followed by the accumulation of a hypophosphorylated form of the Rb protein. In order to determine the effect of the onset of lytic viral replication on cellular events in latently EBV-infected B LCLs, a tightly controlled induction system of the EBV lytic-replication program by inducible BZLF1 protein expression was established in B95-8 cells. The induction of lytic replication completely arrested cell cycle progression and cellular DNA replication. Surprisingly, the levels of p53, p21(WAF-1/CIP-1), and p27(KIP-1) were constant before and after induction of the lytic program, indicating that the cell cycle arrest induced by the lytic program is not mediated through p53 and the CDK inhibitors. Furthermore, although cellular DNA replication was blocked, elevation of cyclin E/A expression and accumulation of hyperphosphorylated forms of Rb protein were observed, a post-G(1)/S phase characteristic of cells. Thus, while the EBV lytic program promoted specific cell cycle-associated activities involved in the progression from G(1) to S phase, it inhibited cellular DNA synthesis. Such cellular conditions appear to especially favor viral lytic replication.
authors.affiliation: Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan.
authors.forename: Ayumi
authors.initials: A
authors.lastname: Kudoh
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Fujita
authors.forename: Tohru
authors.initials: T
authors.lastname: Kiyono
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kuzushima
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sugaya
authors.forename: Shunji
authors.initials: S
authors.lastname: Izuta
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Nishiyama
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Tsurumi
mesh_terms: D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000821:virology*; D001483:Base Sequence; D002455:Cell Division; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017931:DNA Primers; D004261:DNA Replication; D004268:DNA-Binding Proteins / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000502:physiology*; D016196:S Phase; D015534:Trans-Activators / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors; D014764:Viral Proteins; D014779:Virus Replication
chemical_list: C063676:BZLF1 protein, Herpesvirus 4, Human; D017931:DNA Primers; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D015534:Trans-Activators; D016159:Tumor Suppressor Protein p53; D014764:Viral Proteins; D018844:Cyclin-Dependent Kinases